Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding.
| Condition | Intervention | Phase |
|---|---|---|
|
Gastrointestinal Hemorrhage Hematemesis |
Drug: Erythromycin Procedure: gastric lavage |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial. |
- Visual quality of endoscopy [ Time Frame: The endoscopy will be recorded and subsequently it will be evaluated by two endoscopists unaware of the cleaning strategy. The recording's evaluation will be made within the first 30 days after endoscopy ] [ Designated as safety issue: No ]To assess the visual quality of endoscopy the investigators will use the Avgerinos' score modified by Frossard (Gastroenterology 2002;123:17-23). An score from 0 to 2(0 worst vision, where < 25% of the surface was visible. 1, 25-75% visible and 2 >75% visible) was derived from analysis of each area (fundus, body, antrum and bulbus). A score of 6 or greater is considered as a clear stomach, and a score of 5 or lower was considered as a full stomach.
- need for a second-look endoscopy [ Time Frame: within the first 30 days after endoscopy ] [ Designated as safety issue: No ]To assess the need of a second-look endoscopy due to a full stomach during the first endoscopy or due to rebleeding
- need of blood transfusion [ Time Frame: within 30 days after endoscopy ] [ Designated as safety issue: No ]
- number of adverse events as a measure of safety and tolerability [ Time Frame: within the first 30 days after endoscopy ] [ Designated as safety issue: Yes ]
- length of hospitalisation [ Time Frame: within the first 30 days after endoscopy ] [ Designated as safety issue: No ]
- length of endoscopic procedure [ Time Frame: within the first 30 days after endoscopy ] [ Designated as safety issue: No ]
- need for arteriography or surgery [ Time Frame: within the first 30 days after endoscopy ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 122 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: gastric lavage |
Procedure: gastric lavage
gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
|
| Active Comparator: erythromycin |
Drug: Erythromycin
Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
Other Name: Pantomicina Intravenosa
|
Detailed Description:
The researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding.
One hundred and twenty-two patients admitted within 12 hours after hematemesis will be randomly assigned to receive erythromycin infusion or gastric lavage by nasogastric tube prior to emergency endoscopy. The endoscopic procedures will be recorded on Digital Video Disc (DVD). Two endoscopists blinded to the cleansing strategy will assess the quality of examination of the upper gastrointestinal tract by using scales designed by Frossard and Avgerinos .
Secondary endpoints will be the need for a second-look endoscopy, the mean number of blood units transfused, the need of surgery or arteriography, and the mean duration of hospitalization
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- recent hematemesis (<12 hours)
Exclusion Criteria:
- macrolides allergy
- pregnancy or lactation
- treatment with terfenadine, astemizole or cyclosporine
- prior gastrectomy
Contacts and Locations| Contact: Antonio Soriano, M.D. | 0034932607234 | antoniosoriano@bellvitgehospital.cat |
| Spain | |
| Hospital Universitari de Bellvitge | Recruiting |
| L'Hospitalet de Llobregat, Barcelona, Spain, 08907 | |
| Contact: Antonio Soriano, M.D. 0034932607234 antoniosoriano@bellvitgehospital.cat | |
| Principal Investigator: Antonio Soriano, M.D. | |
| Principal Investigator: | Antonio Soriano, M D, Ph D | Hospital Universitari de Bellvitge |
More Information
Publications:
| Responsible Party: | Dr Antonio Soriano Izquierdo, Physician Doctor, Hospital Universitari de Bellvitge |
| ClinicalTrials.gov Identifier: | NCT01716572 History of Changes |
| Other Study ID Numbers: | ERITRO2011 |
| Study First Received: | June 28, 2012 |
| Last Updated: | October 25, 2012 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Keywords provided by Hospital Universitari de Bellvitge:
|
Upper gastrointestinal bleeding Endoscopy Erythromycin Gastric lavage |
Additional relevant MeSH terms:
|
Gastrointestinal Hemorrhage Hematemesis Hemorrhage Gastrointestinal Diseases Digestive System Diseases Pathologic Processes Vomiting Signs and Symptoms, Digestive Signs and Symptoms Erythromycin stearate Erythromycin |
Erythromycin Estolate Erythromycin Ethylsuccinate Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Bacterial Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on May 21, 2013